A novel adeno-associated virus-based genetic vaccine encoding the hepatitis c virus NS3/4 protein exhibits immunogenic properties in mice superior to those of an NS3-protein-based vaccine

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Zhu, Fengqin ^a   Chen, Tian ^a   Zhang, Yeqiong ^a   Sun, Haixia ^a   Cao, Hong ^a   Lu, Jianxi ^a   Zhao, Linshan ^a   Li, Gang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; MESSENGER RNA; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 3 VACCINE; NONSTRUCTURAL PROTEIN 4; NONSTRUCTURAL PROTEIN 4 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; DNA VACCINE; HEPATITIS VACCINE; NS3 PROTEIN, HEPATITIS C VIRUS; NS4 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; GENETIC TRANSDUCTION; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1B; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION; VIRUS TITRATION; ANIMAL; BLOOD; C57BL MOUSE; CYTOLOGY; DEPENDOPARVOVIRUS; FEMALE; GENE VECTOR; GENETICS; HEP-G2 CELL LINE; HEPATITIS C; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM;

ANIMALS; DEPENDOVIRUS; FEMALE; GENETIC VECTORS; HEP G2 CELLS; HEPATITIS C; HUMANS; IMMUNOGLOBULIN G; MICE, INBRED C57BL; RNA, MESSENGER; T-LYMPHOCYTES; VACCINES, DNA; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84953897105     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142349     Document Type: Article

References (49)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001; 345: 41-52. PMID: 11439948
2. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med.2011; 364(13):1195-206. doi: 10.1056/NEJMoa1010494 PMID: 21449783
3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med.2011; 364(25):2405-16. doi: 10.1056/NEJMoa1012912 PMID: 21696307
4. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. N Engl J Med.2014; 370(20):1889-98. doi: 10.1056/NEJMoa1402454 PMID: 24725239
5. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med.2014; 370(16):1483-93. doi: 10.1056/NEJMoa1316366 PMID: 24725238
6. Eisenstein M. Vaccines: a moving target. Nature.2011; 474: S16-S17. doi: 10.1038/474S16a PMID: 21666730
7. Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, et al. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology. 2011; 141: 890-99. doi: 10.1053/j.gastro.2011.06.009 PMID: 21699798
8. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011; 54: 1273-85. doi: 10.1016/j.jhep.2010.09.040 PMID: 21236312
9. Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE, Wiegand J, Schiefke I, et al. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine.2009; 27: 5142-51. doi: 10.1016/j.vaccine.2009.06.027 PMID: 19559112
10. Weiland O, Ahlen G, Diepolder H, Jung MC, Levander S, Fons M, et al. Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Ther.2013; 21:1796-805. doi: 10.1038/mt.2013.119 PMID: 23752314
11. Simmonds P. The origin of hepatitis C virus. Curr Top Microbiol Immunol.2013; 369:1-15. doi: 10.1007/978-3-642-27340-7-1 PMID: 23463195
12. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol.1993; 67: 1385-95. PMID: 7679746
13. Tang H, Grise H. Cellular and molecular biology of HCV infection and hepatitis. Clin Sci (Lond) 2009; 117: 49-65.
14. Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol.2000; 242:55-84. PMID: 10592656
15. Gerlach JT, Ulsenheimer A, Grüner NH, Jung MC, Schraut W, Schirren CA, et al. Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+T-cell epitopes within Hepatitis C virus NS3 and NS4 proteins. J Virol. 2005; 79: 12425-33. PMID: 16160170
16. Thammanichanond D, Moneer S, Yotnda P, Aitken C, Earnest-Silveira L, Jackson D, et al. 2008. Fibermodified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCVspecific T cell response. Clin Immunol.2008; 128: 329-39. doi: 10.1016/j.clim.2008.04.002 PMID: 18524682
17. Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol.1997; 71: 6011-19. PMID: 9223492
18. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitisC virus infection. Lancet.1995; 346: 1006-07. PMID: 7475549
19. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest.1996; 98: 706-14. PMID: 8698862
20. Cerny A, McHutchison JG, Pasquinelli C, Brown ME, Brothers MA, Grabscheid B, et al. Cytotoxic T lymphocyte response to hepatitis C virus-Derived peptides containing the HLA A2.1 binding motif. J Clin Invest.1995; 95:521-30. PMID: 7860734
21. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-Defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol.2003; 77: 6305-13. PMID: 12743287
22. Barefoot B, Thornburg NJ, Barouch DH, Yu JS, Sample C, Johnston RE, et al. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine.2008; 26: 6108-18. doi: 10.1016/j. vaccine.2008.09.007 PMID: 18809447
23. Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2010; 8:62-73. doi: 10.1038/nrmicro2240 PMID: 19966816
24. Lin J, Calcedo R, Vandenberghe LH, Bell P, Somanathan S, Wilson JM. A new genetic vaccine platform based on an adeno-Associated virus isolated from a rhesus macaque. J Virol.2009; 83: 12738-50. doi: 10.1128/JVI.01441-09 PMID: 19812149
25. Logan GJ, Wang L, Zheng M, Coppel RL, Alexander IE. Antigen fusion with C3d3 augments or inhibits humoral immunity to AAV genetic vaccines in a transgene-Dependent manner. Immunol Cell Biol.2010; 88: 228-32. doi: 10.1038/icb.2009.92 PMID: 19935770
26. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet.2011; 12: 341-55. doi: 10.1038/nrg2988 PMID: 21499295
27. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-Associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad.2002; 99: 11854-59.
28. Li X, Cao H, Wang Q, Di B, Wang M, Lu J, et al. Novel AAV-based genetic vaccines encoding truncated dengue virus envelope proteins elicit humoral immune responses in mice. Microbes Infect.2012; 14: 1000-07. doi: 10.1016/j.micinf.2012.05.002 PMID: 22626929
29. Li J, Samulski RJ, Xiao X. Role of highly regulated rep gene expression inadeno-Associated virus vector production. J Virol.1997; 71: 5236-43. PMID: 9188591
30. Xiao X, Li J, Samulski RJ. Efficient long-Term gene transfer into muscle tissue of immunocompetent mice by adeno-Associated virus vector. J Virol.1996; 70: 8098-108. PMID: 8892935
31. Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine.2001; 19, 4652-60. PMID: 11535313
32. Fournillier A, Dupeyrot P, Martin P, Parroche P, Pajot A, Chatel L, et al. Primary and memory T cell responses induced by hepatitis C virus multiepitope long peptides. Vaccine.2006; 24, 3153-64. PMID: 16481078
33. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin Ther Pat.2012; 22:391-415. doi: 10.1517/13543776. 2012.673589 PMID: 22455502
34. Liang TJ. Current progress in development of hepatitis C virus vaccines. Nat Med 2013, 19:869-78. doi: 10.1038/nm.3183 PMID: 23836237
35. Law LMJ, Landi A, Magee WC, Lorne Tyrrell D, Houghton M. Progress towards a hepatitis C virus vaccine. Emerging Microbes & Infections.2013; 2:e79.
36. Fournillier A, Gerossier E, Evlashev A, Schmitt D, Simon B, Chatel L, et al. An accelerated vaccine schedule with a poly-Antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine.2007; 25: 7339-53. PMID: 17875349
37. Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med.2014; 6: 261ra153.
38. Nieto Karen, Salvetti Anna. AAV vectors vaccines against infectious diseases. Front Immunol.2014; 5: 5. doi: 10.3389/fimmu.2014.00005 PMID: 24478774
39. Dismuke DJ, Tenenbaum L, Samulski RJ. Biosafety of recombinant adeno-Associated virus vectors. CurrGeneTher.2013 13:434-52.
40. Vandenberghe LH, Breous E, Nam HJ, Gao G, Xiao R, Sandhu A, et al. Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints. Gene Ther.2009; 16: 1416-28. doi: 10.1038/gt.2009.101 PMID: 19727141
41. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest.2009; 119:1745-54. doi: 10.1172/JCI39133 PMID: 19587449
42. Habersetzer F, Baumert TF, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther.2009; 11: 456-62. PMID: 19649991
43. Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, et al. A Poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic Hepatitis C. Gastroenterology. 2011; 141: 890-99. doi: 10.1053/j.gastro.2011.06.009 PMID: 21699798
44. Huang Y, Uchiyama Y, Fujimura T, Kanamori H, Doi T, Takamizawa A, et al. A human hepatoma cell line expressing hepatitis c virus nonstructural proteins tightly regulated by tetracycline. Biochem Biophys Res Commun.2001; 281: 732-40. PMID: 11237719
45. Frelin L, Alheim M, Chen A, Söderholm J, Rozell B, Barnfield C, et al. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-Expressing tumors in vivo. Gene Ther.2003; 10: 686-99. PMID: 12692597
46. Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB. Strong HCV NS3-and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine.2008; 26:6225-31. doi: 10.1016/j.vaccine.2008.07.052 PMID: 18692108
47. Hügle T, Fehrmann F, Bieck E, Kohara M, Kräusslich HG, Rice CM, et al. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virol.2001; 284: 70-81.
48. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med.2004; 200:1593-604. PMID: 15611288
49. Tanji Y, Hijikata M, Satoh S, Kaneko T, Shimotohno K. Hepatitis C virus-Encoded nonstructural protein NS4A has versatile functions in viral protein processing. J Virol.1995; 69: 1575-81. PMID: 7853491